
UCL Technology Fund (UCLTF) is a venture capital fund dedicated to investing in intellectual property commercialisation opportunities arising from UCL's world-class research base. Managed by AlbionVC in collaboration with UCL Business, it focuses on physical sciences (AI, software, data analytics) and life sciences (gene therapy, medtech), funding spinouts from proof-of-concept through early-stage commercialisation.
Deal activity increased 50% year-over-year (3 deals in the last 12 months). Their most common stage is series-a (55% of deals). Average disclosed round size is $25.0M (across 12 rounds with reported amounts).
Portfolio
20
Fund Size
—
Top Stage
Series A
Last 12 Mo
3
Team
Andrew Elder
Deputy Managing Partner at AlbionVC
Christoph Ruedig
Partner at AlbionVC
David Grimm
Partner
Dr Peter Loudon
Venture Partner
Ed Lascelles
Partner at AlbionVC
Simon Goldman
Partner
Stefanos Theoharis
Venture Partner
Takashi Takenoshita
Venture Partner
Richard Fagan
Director of BioPharm at UCL Business (UCLB)
Leigh Brody
Investment Manager
Sebastian Hunte
Investment Manager
Tanel Ozdemir
Investment Manager
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| Series A | $26M | Jun 2026 | |
| Series A | $8M | Feb 2026 | |
| SStanhope AI | Seed | $8M | Feb 2026 |
| Series A | $33M | Jan 2025 | |
| OOriole | Series A | $22M | Oct 2024 |
| Series A | — | Aug 2024 | |
| Seed | $10M | Jun 2024 | |
| Seed | — | Mar 2024 | |
| Series A | — | Aug 2023 | |
| Series A | $70M | Jul 2023 | |
| IIntrinsic Semiconductor Technologies | Seed | — | Mar 2023 |
| Seed | $4.8M | Nov 2022 | |
| Series A | $4.2M | Jan 2022 | |
| EEpsilogen Ltd | Series A | — | Apr 2020 |
| Unknown | $35M | Jan 2020 | |
| Series B | — | Jan 2020 | |
| Seed | — | Sep 2019 | |
| Seed | — | Jan 2019 | |
| Series A | — | Jan 2017 | |
| HHazy | Series A | $9M | — |
| Unknown | — | — | |
| TTenpoint | Series A | $70M | — |
Top Co-Investors
Last updated: 9 September 2026